Consensus Mesothelin Antigen Vaccine for Cancer Immunotherapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer vaccines targeting tumor cell antigens are limited by poor antigen expression in vivo, necessitating the development of safe and effective vaccines for tumors expressing mesothelin to treat and prevent mesothelin-expressing cancers.

Innovation Solution

Nucleic acid molecules encoding mesothelin antigens or antigenic proteins, including consensus sequences with high identity to native mesothelin, are incorporated into vectors and administered to induce immune responses, potentially combined with immune checkpoint inhibitors to enhance efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing cancer vaccines targeting tumor cell antigens are used, then immune responses are induced, but antigen expression in vivo is poor

Engineering Contradiction:

Improveimmune response inductionVSAvoidantigen expression

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent uses consensus sequences with high identity (≥90%, preferably ≥95% or ≥98%) to native mesothelin to optimize antigen recognition while maintaining immunogenicity. This parameter optimization resolves the contradiction by ensuring sufficient antigen expression and immune response induction simultaneously

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The vaccine combines multiple elements including consensus mesothelin sequences, adjuvants, and potentially immune checkpoint inhibitors in a composite formulation. This composite approach enhances both antigen expression and immune response induction, resolving the technical contradiction

Inventive Principle:

Principle #40Composite materials

2Reliability

If vaccines are developed to target mesothelin-expressing tumors, then therapeutic efficacy is improved, but immune tolerance and suppression must be overcome

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidimmune tolerance and suppression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of immune tolerance and suppression into a benefit by using consensus sequences that deliberately break tolerance. The high identity sequences trigger a beneficial immune response against tumor cells while overcoming the harmful tolerance mechanism

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces adjuvants and potentially immune checkpoint inhibitors as intermediary substances to mediate between the vaccine antigen and the immune system. These intermediaries help overcome immune suppression and enhance therapeutic efficacy

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20240285741A1Cancer vaccines targeting mesothelin and uses thereof

Publication Date: 2024.08.29 INOVIO PHARMACEUTICALS INC

AI summary

Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen are disclosed. Methods of treating a subject with a mesothelin-expressing tumor and methods of preventing a mesothelin-expressing tumor are disclosed. Modified consensus mesothelin antigen is disclosed.